Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stavroula Baritaki

Showing results (61-70 of 77) with videos related to

Pageof 8
Sort By:
Cancer Investigation|February 25, 2009
YY1 Over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levelsStavroula Baritaki, Anthoula M Chatzinikola, Antonios F Vakis, et al.
Journal of Clinical Medicine|July 2, 2021
Methylation Status of Corticotropin-Releasing Factor (CRF) Receptor Genes in Colorectal CancerMaria Panagopoulou, Antonia Cheretaki, Makrina Karaglani, et al.
Nitric Oxide : Biology and Chemistry|December 19, 2012
Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancerSara Huerta-Yepez, Stavroula Baritaki, Guillermina Baay-Guzman, et al.
Cell Cycle (Georgetown, Tex.)|August 9, 2011
Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosisMelisa A Martínez-Paniagua, Stavroula Baritaki, Sara Huerta-Yepez, et al.
Pharmaceutics|March 29, 2023
Discovery of New 1,4,6-Trisubstituted-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridines with Anti-Tumor Efficacy in Mouse Model of Breast CancerMaria Georgiou, Nikolaos Lougiakis, Roxane Tenta, et al.
Cancers|February 25, 2023
Genome-Wide Analysis of lncRNA-mRNA Co-Expression Networks in CD133+/CD44+ Stem-like PDAC CellsGiasemi C Eptaminitaki, Apostolos Zaravinos, Dimitris Stellas, et al.
Journal of Biomedical Materials Research|November 6, 2002
Light scattering and in vitro biocompatibility studies of poly (vinyl pyrrolidone) derivatives with amino-acid-dependent groupsStavroula Baritaki, George N Tzanakakis, John Alifragis, et al.
Peptides|April 26, 2020
Corticotropin Releasing Factor Receptors in breast cancer: Expression and activity in hormone-dependent growth in vitroMaria Koureta, Makrina Karaglani, Maria Panagopoulou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2008
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cellsStavroula Baritaki, Eriko Suzuki, Kazuo Umezawa, et al.
Forum on Immunopathological Diseases and Therapeutics|November 29, 2013
Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple MyelomaStavroula Baritaki, Sara Huerta-Yepez, Ma da Lourdas Cabrava-Haimandez, et al.
Pageof 8

Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
Cancer Investigation|February 25, 2009
YY1 Over-expression in human brain gliomas and meningiomas correlates with TGF-beta1, IGF-1 and FGF-2 mRNA levelsStavroula Baritaki, Anthoula M Chatzinikola, Antonios F Vakis, et al.
Journal of Clinical Medicine|July 2, 2021
Methylation Status of Corticotropin-Releasing Factor (CRF) Receptor Genes in Colorectal CancerMaria Panagopoulou, Antonia Cheretaki, Makrina Karaglani, et al.
Nitric Oxide : Biology and Chemistry|December 19, 2012
Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancerSara Huerta-Yepez, Stavroula Baritaki, Guillermina Baay-Guzman, et al.
Cell Cycle (Georgetown, Tex.)|August 9, 2011
Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosisMelisa A Martínez-Paniagua, Stavroula Baritaki, Sara Huerta-Yepez, et al.
Pharmaceutics|March 29, 2023
Discovery of New 1,4,6-Trisubstituted-1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridines with Anti-Tumor Efficacy in Mouse Model of Breast CancerMaria Georgiou, Nikolaos Lougiakis, Roxane Tenta, et al.
Cancers|February 25, 2023
Genome-Wide Analysis of lncRNA-mRNA Co-Expression Networks in CD133+/CD44+ Stem-like PDAC CellsGiasemi C Eptaminitaki, Apostolos Zaravinos, Dimitris Stellas, et al.
Journal of Biomedical Materials Research|November 6, 2002
Light scattering and in vitro biocompatibility studies of poly (vinyl pyrrolidone) derivatives with amino-acid-dependent groupsStavroula Baritaki, George N Tzanakakis, John Alifragis, et al.
Peptides|April 26, 2020
Corticotropin Releasing Factor Receptors in breast cancer: Expression and activity in hormone-dependent growth in vitroMaria Koureta, Makrina Karaglani, Maria Panagopoulou, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 22, 2008
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cellsStavroula Baritaki, Eriko Suzuki, Kazuo Umezawa, et al.
Forum on Immunopathological Diseases and Therapeutics|November 29, 2013
Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple MyelomaStavroula Baritaki, Sara Huerta-Yepez, Ma da Lourdas Cabrava-Haimandez, et al.
Pageof 8